Page 137 - 《中国药房》2022年18期

twenty[J]. Immunity，2012，36（4）：503-514. [22] MUKHERJEE A，HAZRA A，SMITH M K，et al.
[ 9 ] SOENDERGAARD C，BERGENHEIM F H，BJERRUM Exposure-response characterization of tofacitinib efficacy
J T，et al. Targeting JAK-STAT signal transduction in IBD in moderate to severe ulcerative colitis：results from a
[J]. Pharmacol Ther，2018，192：100-111. dose-ranging phase 2 trial[J]. Br J Clin Pharmacol，2018，
[10] O’SHEA J J，HOLLAND S M，STAUDT L M. JAKs and 84（6）：1136-1145.
STATs in immunity，immunodeficiency，and cancer[J]. N [23] SANDBORN W J，GHOSH S，PANES J，et al. Tofaci‐
Engl J Med，2013，368（2）：161-170. tinib，an oral Janus kinase inhibitor，in active ulcerative
[11] VILLARINO A V，KANNO Y，O'SHEA J J. Mechanisms colitis[J]. N Engl J Med，2012，367（7）：616-624.
and consequences of JAK-STAT signaling in the immune [24] SANDBORN W J，SU C，SANDS B E，et al. Tofacitinib
system[J]. Nat Immunol，2017，18（4）：374-384. as induction and maintenance therapy for ulcerative colitis
[12] MCGOVERN D P，GARDET A，TÖRKVIST L，et al. [J]. N Engl J Med，2017，376（18）：1723-1736.
Genome-wide association identifies multiple ulcerative [25] VERMEIRE S，SU C，LAWENDY N，et al. Outcomes of
colitis susceptibility loci[J]. Nat Genet，2010，42（4）： tofacitinib dose reduction in patients with ulcerative coli‐
332-337. tis in stable remission from the randomised RIVETING
[13] ANDERSON C A，BOUCHER G，LEES C W，et al. Meta- trial[J]. J Crohns Colitis，2021，15（7）：1130-1141.
analysis identifies 29 additional ulcerative colitis risk loci， [26] SANDS B E，ARMUZZI A，MARSHALL J K，et al. Effi‐
increasing the number of confirmed associations to 47[J]. cacy and safety of tofacitinib dose de-escalation and dose
Nat Genet，2011，43（3）：246-252. escalation for patients with ulcerative colitis：results from
[14] JOSTINS L，RIPKE S，WEERSMA R K，et al. Host- OCTAVE open[J]. Aliment Pharmacol Ther，2020，51（2）：
microbe interactions have shaped the genetic architecture 271-280.
of inflammatory bowel disease[J]. Nature，2012，491 [27] PANÉS J，VERMEIRE S，DUBINSKY M C，et al. Effi‐
（7422）：119-124. cacy and safety of tofacitinib re-treatment for ulcerative
[15] BOLAND B S，SANDBORN W J，CHANG J T. Update colitis after treatment interruption：results from the
on Janus kinase antagonists in inflammatory bowel disease OCTAVE clinical trials[J]. J Crohns Colitis，2021，15
[J]. Gastroenterol Clin North Am，2014，43（3）：603-617. （11）：1852-1863.
[16] FERNÁNDEZ-CLOTET A， CASTRO-POCEIRO J， [28] PANÉS J，VERMEIRE S，LINDSAY J O，et al. Tofaci‐
PANÉS J. Tofacitinib for the treatment of ulcerative colitis tinib in patients with ulcerative colitis：health-related qua-
[J]. Expert Rev Clin Immunol，2018，14（11）：881-892. lity of life in phase 3 randomised controlled induction and
[17] SPALINGER M R，SAYOC-BECERRAA，ORDOOKHANIAN maintenance studies[J]. J Crohns Colitis，2018，12（2）：
C，et al. The JAK inhibitor tofacitinib rescues intestinal 145-156.
barrier defects caused by disrupted epithelial-macrophage [29] JAMESHORANI M，VAHEDI H，SADEGHI A，et al. Ef‐
interactions[J]. J Crohns Colitis，2021，15（3）：471-484. ficacy and safety of tofacitinib for treatment of moderate
[18] SAYOC-BECERRA A，KRISHNAN M，FAN S J，et al. to severe active ulcerative colitis：first report from Iran[J].
The JAK-inhibitor tofacitinib rescues human intestinal epi‐ Arch Iran Med，2021，24（5）：354-363.
thelial cells and colonoids from cytokine-induced barrier [30] LAIR-MEHIRI L，STEFANESCU C，VAYSSE T，et al.
dysfunction[J]. Inflamm Bowel Dis，2020，26（3） ： Real-world evidence of tofacitinib effectiveness and
407-422. safety in patients with refractory ulcerative colitis[J]. Dig
[19] CORDES F，LENKER E，SPILLE L J，et al. Tofacitinib Liver Dis，2020，52（3）：268-273.
reprograms human monocytes of IBD patients and healthy [31] BIEMANS V B C，SLEUTJES J A M，DE VRIES A C，et
controls toward a more regulatory phenotype[J]. Inflamm al. Tofacitinib for ulcerative colitis：results of the prospec‐
Bowel Dis，2020，26（3）：391-406. tive Dutch Initiative on Crohn and Colitis（ICC）registry
[20] DOWTY M E，LIN J Y，RYDER T F，et al. The pharmaco‐ [J]. Aliment Pharmacol Ther，2020，51（9）：880-888.
kinetics，metabolism，and clearance mechanisms of tofaci‐ [32] UZZAN M，BRESTEAU C，LAHARIE D，et al. Tofaci‐
tinib，a Janus kinase inhibitor，in humans[J]. Drug Metab tinib as salvage therapy for 55 patients hospitalised with
Dispos，2014，42（4）：759-773. refractory severe ulcerative colitis：a GETAID cohort[J].
[21] Pfizer. Pfizer announces U.S. FDA approves Xeljanz（to‐ Aliment Pharmacol Ther，2021，54（3）：312-319.
facitinib）for the treatment of moderately to severely ac‐ [33] BERINSTEIN J A，SHEEHAN J L，DIAS M，et al. Tofaci‐
tive ulcerative colitis[EB/OL].（2018-05-30）[2022-02-08]. tinib for biologic-experienced hospitalized patients with
https：//www. pfizer. com/news/press-release/press-release- acute severe ulcerative colitis：aretrospective case-control
detail/pfizer_announces_u_s_fda_approves_xeljanz_to ‐ study[J]. Clin Gastroenterol Hepatol，2021，19（10）：2112-
facitinib_for_the_treatment_of_moderately_to_severely_ 2120.e1.
active_ulcerative_colitis-0. [34] SHAFFER S R，HUANG E，PATEL S，et al. Cost-

中国药房 2022年第33卷第18期 China Pharmacy 2022 Vol. 33 No. 18 ·2303·